A New Era in Protein Design

Latent Labs is shaking up the scientific community with the launch of a pioneering web-based AI model, just six months after securing a whopping $50 million in funding. This innovative tool aims to democratize protein design, making cutting-edge biological programming accessible to everyone.

State-of-the-Art Performance

According to CEO and founder Simon Kohl, a notable scientist from DeepMind’s AlphaFold team, their model has achieved state-of-the-art (SOTA) results in various testing metrics. This term denotes superior performance in the field of AI, showcasing the efficacy of the proteins developed through their software.

High Viability Rates

Kohl revealed to TechCrunch that a significant percentage of the proteins generated by their model are not only theoretical but also viable in laboratory environments. This marks a huge leap forward in the practical application of AI in biology.

Meet LatentX: Your Browser-Based Lab

Named LatentX, this groundbreaking model allows academia, biotech startups, and pharmaceutical giants to design novel proteins using simple natural language commands—all from the comfort of their web browsers. Imagine tapping into a vast potential for new therapeutics at an unprecedented speed!

Going Beyond Nature

What sets LatentX apart from existing solutions like AlphaFold is its ability to create entirely new molecular designs, including advanced forms like nanobodies and antibodies with precise atomic arrangements. This could revolutionize therapeutic development.

A License to Innovate

Unlike companies that focus solely on developing proprietary drugs, Latent Labs is positioning itself uniquely by offering licenses to external organizations. Kohl emphasizes that not every company has the resources to build their own AI infrastructure, making their model an essential tool for those in the field.

Free Access with Future Potential

While LatentX is currently available for free, Kohl hinted at future plans to introduce premium features at a cost. This innovative approach places cutting-edge technology within reach of those who need it most.

A Supportive Network

Latent Labs is not alone in this venture. It has the backing of notable firms and figures, including Radical Ventures and Google's Chief Scientist Jeff Dean, ensuring that the model not only thrives but pushes the boundaries of what's possible in drug discovery.